Overview of the mutational landscape in primary myelofibrosis and advances in novel therapeutics

Medicine and Dentistry

• Allogeneic Hematopoietic Stem Cell Transplantation 33%
• ASXL1 33%
• Bleeding Diathesis 33%
• Decitabine 33%
• Everolimus 33%
• Fibrosis 33%
• Ganetespib 33%
• Givinostat 33%
• Glasdegib 33%
• Histone Deacetylase Inhibitor 33%
• Hsp90 Inhibitor 33%
• Hypomethylating Agent 33%
• Janus Kinase 33%
• Janus Kinase Inhibitor 33%
• Mammalian Target of Rapamycin Inhibitor 33%
• Myeloid metaplasia 100%
• Myeloproliferative Neoplasm 33%
• Panobinostat 33%
• Pracinostat 33%
• Protein Kinase B 33%
• Ruxolitinib 33%
• Telomerase Inhibitor 33%
• Thrombosis 33%
• Treatment Option 66%
• Vorinostat 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Bleeding Tendency 33%
• Decitabine 33%
• Everolimus 33%
• Fibrosis 33%
• Ganetespib 33%
• Givinostat 33%
• Glasdegib 33%
• Heat Shock Protein 90 Inhibitor 33%
• Hedgehog 33%
• Histone Deacetylase Inhibitor 33%
• Janus Kinase 33%
• Janus Kinase Inhibitor 33%
• Mammalian Target of Rapamycin Inhibitor 33%
• Myeloid metaplasia 100%
• Myeloproliferative Neoplasm 33%
• Panobinostat 33%
• Pracinostat 33%
• Protein Kinase B 33%
• Ruxolitinib 33%
• Telomerase Inhibitor 33%
• Thrombosis 33%
• Vorinostat 33%